Search | Invivogen

ODN 2006 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Human) | Th1 response

Species-driven TLR9 differential responses

NF-κB response induced by ODN 2006

IRF response induced by ODN 2006

ODN TTAGGG (A151) - TLR9 Antagonist

TLR9, AIM2, and cGAS antagonist

TLR9 signaling inhibition

Specific AIM2 inflammasome signaling inhibition

CDS signaling inhibition

ODN 4084-F - TLR9 Antagonist

Class B inhibitory ODN

Dose-dependent inhibition of TLR9 activity by ODN 4084-F

ODN 2088 control - TLR9 Ligand

Negative control for ODN 2088

Dose-dependent inhibition of TLR9 activity in HEK-Blue™ mTLR9 cells.

ODN 2088 - TLR9 Antagonist

Inhibitory ODN, preference towards mouse

Dose-dependent inhibition of TLR9 activity by ODN 2088

ODN 1585 - TLR9 Agonist

Stimulatory CpG ODN, Class A, Mouse-preferred

Dose-dependent NF-κB response of ODN 1585 in HEK-Blue™ mTLR9 cells

NF-κB and IRF responses of ODN 1585 in THP1-Dual™ hTLR9 cells

E. coli ssDNA / LyoVec™ - TLR9 Agonist

E. coli single stranded DNA / LyoVec™ complexed

Dose-dependent response of E. coli ssDNA/LyoVec™ in THP1-Blue™ ISG cells

ODN TTAGGG control - TLR9 Ligand

Negative control for ODN TTAGGG

Dose-dependent inhibition of TLR9 activity in HEK-Blue™ hTLR9 cells

ODN 1826 FITC - TLR9 Agonist

FITC-labeled CpG ODN, Class B, Mouse-preferred

Detection of ODN 1826 FITC

ODN 1826 Biotin - TLR9 Agonist

Biotin-labeled CpG ODN 1826, Class B, Mouse-preferred

Detection of ODN 1826 Biotin

ODN 2216 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Human) | Th1 response

Dose-dependent NF-κB response of ODN 2216 in HEK-Blue™ hTLR9 cells

Dose-dependent NF-κB and IRF responses in THP1-Dual™ hTLR9 cells

ODN 1826 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Mouse) | Th1 response

NF-κB response of ODN 1826 in HEK-Blue™-derived cells

NF-κB and IRF responses of ODN 1826 in THP1-Dual™ hTLR9 cells

MPLA-SM VacciGrade™- TLR4-based Adjuvant

Monophosphoryl lipid A | Th1 response

Activation of mouse and human TLR4

Absence of TLR2-activating contaminants

Imiquimod VacciGrade™ (R837) - TLR7-based Adjuvant

Imidazoquinoline compound | Th1 response

NF-κB response of HEK-Blue™-derived cells to imiquimod

NF-κB and IRF responses of HEK-Dual™-derived cells to imiquimod

Flagellin FliC VacciGrade™ - TLR5-based Adjuvant

Recombinant flagellin from S. typhimurium | Th1/Th2 response

Rec FLA-ST dose-dependent activation of TLR5

IFA

Incomplete Freund's adjuvant | Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA

Alhydrogel® adjuvant 2%

Aluminium hydroxide gel | Th2 Response

Antibody responses to OVA with different adjuvants

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with Alhydrogel® adjuvant 2%

AddaVax™

Squalene-Oil-in-water | Th1/Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with AddaVax™

ODN 1826 control (ODN 2138) - TLR9 Ligand

Negative control for ODN 1826

Dose-dependent NF-κB response in HEK-Blue™ mTLR9 cells.

ODN 1826 - TLR9 Agonist

Stimulatory CpG ODN, Class B, Mouse-preferred

NF-κB response of ODN 1826 in HEK-Blue™-derived cells

NF-κB and IRF responses of ODN 1826 in THP1-Dual™ hTLR9 cells